TY - JOUR
T1 - The biphasic role of NF-κB in progression and chemoresistance of ovarian cancer
AU - Yang, Gong
AU - Xiao, Xue
AU - Rosen, Daniel G.
AU - Cheng, Xi
AU - Wu, Xiaohua
AU - Chang, Bin
AU - Liu, Guangzhi
AU - Xue, Fengxia
AU - Mercado-Uribe, Imelda
AU - Chiao, Paul
AU - Du, Xiang
AU - Liu, Jinsong
PY - 2011/4/15
Y1 - 2011/4/15
N2 - Purpose: NF-κB is a transcription factor known to promote tumorigenesis. However, NF-κB is also known to be proapoptotic and may potentially function as a tumor suppressor, although such a functional role has not been extensively investigated in human cancer. Experimental Design: A dominant-negative mutant of IkBa with mutations at S32A and S36A was used to inhibit the function of NF-κB in ovarian cancer cell lines. The transcription ability, tumorigenesis, apoptosis, and drug sensitivity were examined in derivative cell lines in comparison with parental cells. We also analyzed the association of nuclear expression of NF-κB p65 with patient survival in an ovarian cancer tissue array. Results: We show that NF-κB functions as a tumor suppressor in four ovarian cancer cell lines, but it functions as an oncogene in their aggressive chemoresistant isogenic variants. NF-kB can exert its proapoptotic or antiapoptotic effect by activating or repressing mitogen-activated protein kinase (MAPK) phosphorylation in parental or aggressive chemoresistant variant cell lines. We also show that the nuclear accumulation of p65 in epithelial cancer tissue is associated with a good response to chemotherapy and can predict longer overall survival for patients with ovarian cancer. Conclusions: Our data provide strong evidence that NF-κB can function as a biphasic regulator, either suppressing or enhancing ovarian cancer growth through the regulation of MAPK and cellular apoptosis.
AB - Purpose: NF-κB is a transcription factor known to promote tumorigenesis. However, NF-κB is also known to be proapoptotic and may potentially function as a tumor suppressor, although such a functional role has not been extensively investigated in human cancer. Experimental Design: A dominant-negative mutant of IkBa with mutations at S32A and S36A was used to inhibit the function of NF-κB in ovarian cancer cell lines. The transcription ability, tumorigenesis, apoptosis, and drug sensitivity were examined in derivative cell lines in comparison with parental cells. We also analyzed the association of nuclear expression of NF-κB p65 with patient survival in an ovarian cancer tissue array. Results: We show that NF-κB functions as a tumor suppressor in four ovarian cancer cell lines, but it functions as an oncogene in their aggressive chemoresistant isogenic variants. NF-kB can exert its proapoptotic or antiapoptotic effect by activating or repressing mitogen-activated protein kinase (MAPK) phosphorylation in parental or aggressive chemoresistant variant cell lines. We also show that the nuclear accumulation of p65 in epithelial cancer tissue is associated with a good response to chemotherapy and can predict longer overall survival for patients with ovarian cancer. Conclusions: Our data provide strong evidence that NF-κB can function as a biphasic regulator, either suppressing or enhancing ovarian cancer growth through the regulation of MAPK and cellular apoptosis.
UR - http://www.scopus.com/inward/record.url?scp=79954612742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954612742&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-3265
DO - 10.1158/1078-0432.CCR-10-3265
M3 - Article
C2 - 21339307
AN - SCOPUS:79954612742
SN - 1078-0432
VL - 17
SP - 2181
EP - 2194
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -